top of page

Weight Management

Liraglutide (Saxenda®) PGD Training 

Saxenda webinar and PGD-accredited services for pharmacists and

allied healthcare professionals. 

Courses >   Weight Management - Liraglutide (Saxenda®)

Weight Management

​Liraglutide (Saxenda®)

PGD Training 

Liraglutide (Saxenda®) PGD Training 2020/21

Expert Clinic (EC) and Voyager Medical (VM) have jointly organised the Saxenda webinar and PGD-accredited services for pharmacists and allied healthcare professionals.

The EC and VM training programme has two parts:

  • Part (I) –  Webinar

  • Part (II) – PGD online assessment with support materials


What is Liraglutide (Saxenda®)

The Liraglutide (Saxenda®) 3mg injection is an injectable prescription medicine that is licensed -:

As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of

  • ≥30 kg/m² (obese), or

  • ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.


How Liraglutide (Saxenda®) Works

Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) analogue with 97% amino acid sequence homology to endogenous human GLP-1. Liraglutide binds to and activates the GLP-1 receptor (GLP-1R).

GLP-1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear. In animal studies, peripheral administration of liraglutide led to uptake in specific brain regions involved in regulation of appetite, where liraglutide, via specific activation of the GLP-1R, increased key satiety and decreased key hunger signals, thereby leading to lower body weight.

GLP-1 receptors are also expressed in specific locations in the heart, vasculature, immune system and kidneys. In mouse models of atherosclerosis, liraglutide prevented aortic plaque progression and reduced inflammation in the plaque. In addition, liraglutide had a beneficial effect on plasma lipids.

Liraglutide did not reduce the plaque size of already established plaques.

Overview of Training Content

  • Obesity as a Disease.

  • Current Management of Obesity in the United Kingdom.

  • Glucagon-like Peptide-1 (GLP-1) and Liraglutide (Saxenda)

  • SCALE Clinical Programme on efficacy and safety profile of Liraglutide (Saxenda)

  • The XENSOR Study – Real-world study comparing effectiveness and tolerability of Orlistat and Liraglutide

  • Safety Profile and Requirements for Liraglutide

  • Practical Considerations on Liraglutide (Saxenda) – demonstration using Saxenda placebo pen by trainer.

  • How to set up a weight management clinic in a pharmacy setting using Voyager Medical’s accredited PGDs on weightmanagement.


* You will be directed to Google Forms to enrol onto this course.

For further information, please email: and CC (carbon copy) or Whatsapp messaging or voice note to 07894435050 (Whatsapp only, please do not call) 

If the matter is urgent, please call  0207 993 2544 / 07776491974.

Training Accreditation and Support

After the completion of the online face-to-face training, healthcare professionals will be required to complete and pass an online PGD-accredited examination/assessment.  

After the accreditation, healthcare professionals will be able to access Voyager Medical’s PGD and other relevant documents, such as a risk assessment form (RAF). The Expert Clinic and Voyager Medical clinical governance process will require Liraglutide (Saxenda®) Webinar Training and PGD; once completed and accredited, this certification will last for one year with a requirement upon expiry for annual renewal for updates and re-accreditations.

Continue Reading Weight Management

Course Material - Password protected, for existing students only*

Existing students only*

New students only*

bottom of page